Overview

A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to estimate the effects of different strong enzyme (CYP3A4) inhibitors, itraconazole, diltiazem, or verapamil on the single dose pharmacokinetics of PF-00489791 in healthy volunteers. The study will enroll approximately 18 subjects that are randomized to 1 of 3 treatment groups. The study is also intended to determine the safety and tolerability of single-dose PF- 00489791 when it is administered with steady-state itraconazole, diltiazem, or verapamil.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Cytochrome P-450 CYP3A Inhibitors
Diltiazem
Hydroxyitraconazole
Itraconazole
Verapamil